Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 13/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.35 |
| ▸ | HTR3B | O95264 | 2/20 | 0.35 |
| ▸ | HTR3A | P46098 | 2/20 | 0.35 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.35 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1177513 | 0.88 | PDE3B (0.39) | HCRTR2HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL1177445 | 0.86 | KCNH2 (0.35) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL1178259 | 0.86 | HCRTR2 (0.36) | HCRTR2KDM4EALDH1A1HTR3EHTR3B | |
| SCHEMBL1177414 | 0.85 | KCNH2 (0.35) | — | |
| SCHEMBL1177349 | 0.84 | KCNH2 (0.36) | — | |
| SCHEMBL1178031 | 0.84 | KCNH2 (0.34) | — | |
| SCHEMBL1178238 | 0.84 | HTR3E (0.37) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL1177485 | 0.83 | HCRTR2 (0.36) | HCRTR2KDM4EHTR3EHTR3BHTR3A | |
| SCHEMBL1178143 | 0.82 | HCRTR2 (0.36) | HCRTR2HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL1177619 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112139-A1 | NOVEL 8-AZA-BICYCLO[3.2.1]OCTANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | PETERS DAN | 2011-05-12 | — | — | US | disclosed |
| US-7888358-B2 | Serotonine, dopamine and norendrenaline receptors; antidepressants, anxiolytic agents, eating disorders; obesity; bipolar; drug abuse; neurodegenerative diseases | NEUROSEARCH A/S (DK) | 2011-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112139-A1 | NOVEL 8-AZA-BICYCLO[3.2.1]OCTANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | SLC18A2, SLC18A3, SLC6A2 | HCRTR2 61/4885KDM4E 452/4885ALDH1A1 535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.